Riluzole as a Potential Therapeutic Agent for Chagas Disease: A Comprehensive Scientific Review
SSRN Electronic Journal · 2026
DOI: 10.2139/ssrn.6376298 ↗Kurz gefasst
Fachartikel in der Zeitschrift SSRN Electronic Journal, 2026. Verfasst von Edward Matthews.
Abstract (Originalsprache)
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, affects over 7 million people worldwide and results in approximately 10,000 deaths annually. Current treatment options, benznidazole and nifurtimox, are limited by significant adverse effects, variable efficacy, and lengthy treatment durations. This comprehensive review examines the potential of riluzole, an FDA-approved neuroprotective agent, as a novel therapeutic approach for Chagas disease. Through analysis of recent research on riluzole's antiparasitic properties, mechanism of action involving glutamate modulation and pteridine reductase inhibition, and favorable safety profile, we present evidence supporting riluzole's repurposing for this neglected tropical disease. The review integrates findings from multiple studies demonstrating riluzole's activity against various parasites, including Leishmania species and Entamoeba histolytica, and explores potential combination therapy approaches. Comparative analysis of dosing regimens, adverse effect profiles, and therapeutic efficacy suggests that riluzole may offer significant advantages over current standard treatments, particularly in reducing treatment-related toxicity while maintaining antiparasitic activity.
Zitieren
APA
Matthews, E. (2026). Riluzole as a Potential Therapeutic Agent for Chagas Disease: A Comprehensive Scientific Review. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.6376298
Vancouver
Matthews E. Riluzole as a Potential Therapeutic Agent for Chagas Disease: A Comprehensive Scientific Review. SSRN Electronic Journal. 2026. doi:10.2139/ssrn.6376298
BibTeX
@article{Matthews2026,
author = {Matthews, Edward},
title = {Riluzole as a Potential Therapeutic Agent for Chagas Disease: A Comprehensive Scientific Review},
journal = {SSRN Electronic Journal},
year = {2026},
doi = {10.2139/ssrn.6376298}
}
EUVIMED